David A. Siegel Adicet Bio, Inc. Transaction History

Two Sigma Advisers, LP

$42.8 Billion
Q1 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 622,839 shares of ACET stock, worth $417,302. This represents 0.0% of its overall portfolio holdings.

Number of Shares

622,839

Previous 794,039 21.56%

Holding current value

$417,302

Previous $762,000 37.93%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.76 - $1.09 $130,112 - $186,608	-171,200 Reduced 21.56%	622,839 $473,000
Q4 2024 Feb 14, 2025	BUY	$0.86 - $1.52 $75,164 - $132,848	87,400 Added 12.37%	794,039 $762,000
Q3 2024 Nov 14, 2024	BUY	$1.07 - $1.63 $108,605 - $165,445	101,500 Added 16.77%	706,639 $1.02 Million
Q2 2024 Aug 14, 2024	BUY	$1.21 - $2.4 $119,911 - $237,840	99,100 Added 19.58%	605,139 $732,000
Q1 2024 May 15, 2024	SELL	$1.76 - $3.45 $24,640 - $48,300	-14,000 Reduced 2.69%	506,039 $1.19 Million
Q4 2023 Feb 14, 2024	BUY	$1.11 - $1.89 $148,010 - $252,018	133,343 Added 34.48%	520,039 $982,000
Q3 2023 Nov 14, 2023	BUY	$1.37 - $3.4 $386,203 - $958,460	281,900 Added 269.0%	386,696 $529,000
Q2 2023 Aug 14, 2023	BUY	$2.13 - $7.13 $26,625 - $89,125	12,500 Added 13.54%	104,796 $254,000
Q1 2023 May 15, 2023	SELL	$5.52 - $9.23 $491,279 - $821,470	-89,000 Reduced 49.09%	92,296 $531,000
Q4 2022 Feb 14, 2023	SELL	$7.72 - $21.27 $226,968 - $625,338	-29,400 Reduced 13.95%	181,296 $1.62 Million
Q3 2022 Nov 14, 2022	SELL	$13.43 - $18.74 $1.03 Million - $1.44 Million	-76,800 Reduced 26.71%	210,696 $3 Million
Q2 2022 Aug 15, 2022	BUY	$10.26 - $20.81 $119,016 - $241,395	11,600 Added 4.2%	287,496 $4.2 Million
Q1 2022 May 16, 2022	BUY	$11.53 - $19.97 $532,686 - $922,614	46,200 Added 20.11%	275,896 $5.51 Million
Q4 2021 Feb 14, 2022	BUY	$7.37 - $17.49 $1.17 Million - $2.77 Million	158,615 Added 223.15%	229,696 $4.02 Million
Q3 2021 Nov 15, 2021	SELL	$6.29 - $9.93 $242,165 - $382,305	-38,500 Reduced 35.13%	71,081 $557,000
Q2 2021 Aug 16, 2021	BUY	$9.19 - $15.93 $305,108 - $528,876	33,200 Added 43.47%	109,581 $1.13 Million
Q1 2021 May 17, 2021	BUY	$12.12 - $17.17 $562,368 - $796,688	46,400 Added 154.76%	76,381 $999,000
Q4 2020 Feb 16, 2021	SELL	$10.36 - $14.77 $109,660 - $156,340	-10,585 Reduced 26.09%	29,981 $421,000
Q3 2020 Nov 16, 2020	BUY	$10.18 - $21.4 $412,961 - $868,112	40,566 New	40,566 $482,000

Others Institutions Holding ACET

# of Institutions

Shares Held

57.5M

Call Options Held

36.9K

Put Options Held

16.5K

View Full List

About Adicet Bio, Inc.

Ticker ACET
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,030,800
Market Cap $26.8M
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...

More about ACET

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account